Wegovy in India: Price, Dose & Results

Wegovy is semaglutide, a GLP-1 receptor agonist that mimics a gut hormone to reduce appetite, slow stomach emptying and steady blood sugar. The molecule is identical to Ozempic's. What differs is the licence and the dose:

• Wegovy — licensed for weight management, titrating to 2.4 mg weekly.
• Ozempic — licensed for type 2 diabetes, capped at 2.0 mg weekly.

If weight loss is the goal, Wegovy is the product designed for it at the dose the evidence was generated on. That is the entire distinction, and it is the one most people searching for “Ozempic for weight loss” are missing.

Wegovy pricing changed materially this year. Semaglutide's Indian patent expired on 20 March 2026, more than 40 generic versions launched at roughly ₹1,300–₹4,200 per month, and branded Wegovy was reduced by up to 48% in response.

So the honest comparison is no longer “Wegovy versus nothing” but “branded Wegovy versus approved generic semaglutide”. The branded product carries the weight-management licence and a known manufacturing chain; approved generics carry the same molecule at lower cost. Both are legitimate; the choice is clinical and financial rather than obvious.

Wegovy is titrated upward over about four months. The escalation is not bureaucracy — it is what makes the drug tolerable, and rushing it is the most common reason people abandon treatment in the first month.

The standard schedule steps through 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, roughly four weeks at each step, with your clinician holding you at a step for longer if side effects need it. The early doses are there to build tolerance; they are not expected to produce much weight loss on their own — see the table below.

In STEP 1, adults with overweight or obesity lost an average of about 15% of body weight over 68 weeks on 2.4 mg weekly plus lifestyle support. Averages hide a wide spread: some people lose considerably more, a minority respond poorly.

Semaglutide also has hard outcome data behind it. In SELECT, adults with overweight or obesity and existing cardiovascular disease but not diabetes had a 20% reduction in major adverse cardiovascular events — evidence about health, not just the number on a scale.

The part worth planning for: a meaningful share of lost weight is lean mass unless you deliberately protect it. Adequate protein and resistance training are not optional add-ons to a GLP-1 programme; they are what determines whether you end up lighter or simply smaller.

The common effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation — strongest in the first weeks and after each dose step, and easing for most people within a month or two.

Less common but serious risks include pancreatitis and gallbladder disease. Semaglutide carries a boxed warning for thyroid C-cell tumours from rodent studies, and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. It should not be used in pregnancy, and should be stopped well before a planned pregnancy.